Application and Use of Transformative Emerging Technologies in Cancer Research (R33)

The summary for the Application and Use of Transformative Emerging Technologies in Cancer Research (R33) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Application and Use of Transformative Emerging Technologies in Cancer Research (R33): Purpose. This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing exceptionally innovative, high risk, original and/or unconventional research projects focused on evaluating the performance of emerging, potentially transformative molecular and cellular analysis technologies within the context of an appropriate cancer-relevant biological system. The emphasis of this FOA is on the application of emerging molecular and cellular analysis tools with the potential to (i) create new or challenge existing scientific and technological paradigms and/or (ii) overcome technological barriers in important areas of cancer research. Projects must clearly demonstrate potential to produce a major impact in a broad area of biomedical or cancer-relevant research through application to a relevant biological system. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Several IMAT FOAs of identical or closely related scientific scope using various funding mechanisms are available. To facilitate selection, a separate Notice in the NIH Guide for Grants and Contracts provides brief cross-comparison and links to all the IMAT FOAs. See NOT-CA-09-007.
Federal Grant Title: Application and Use of Transformative Emerging Technologies in Cancer Research (R33)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-09-007
Type of Funding: Grant
CFDA Numbers: 93.392
CFDA Descriptions: Cancer Construction
Current Application Deadline: Sep 30, 2009
Original Application Deadline: Sep 30, 2009
Posted Date: Dec 15, 2008
Creation Date: Dec 15, 2008
Archive Date: Oct 31, 2009
Total Program Funding: $1,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
Epigenetic Approaches in Cancer Epidemiology (R01)
Innovative and Applied Emerging Technologies in Biospecimen Science (R33)
Innovative and Applied Emerging Technologies in Biospecimen Science (R21)
Innovative Technology Development for Cancer Research (R21)
Application and Use of Transformative Emerging Technologies in Cancer Research (R21)
Small Grants Program for Cancer Epidemiology (R03)
More Grants from the National Institutes of Health
Drug Screening with Biofabricated 3-D Skin Disease Tissue Models (U18 Clinical Trial Not A...
Postdoctoral Research Associate Training (PRAT) Program (Fi2)
Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation (S...
Sponsored Programs Administration Development (SPAD) Program (UC2 - Clinical Trial Not All...
PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com